News
-
-
COMMUNIQUÉ DE PRESSE
Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer's disease transgenic model to be presented at AD/PD™ 2024 Conference
Galimedix Therapeutics to present new pre-clinical data with GAL-201 in an Alzheimer's disease transgenic model at AD/PD™ 2024 Conference, showing promise in targeting amyloid beta oligomers and protofibrils -
COMMUNIQUÉ DE PRESSE
Galimedix Appoints Dr. Luciana Summo as Vice President, R&D Operations